Contact

Prothrombin (Factor II) Deficiency

References

  1. Quick AJ. Congenital familial hypoprothrombinemias. Proc Annu Meet Cent Soc Clin Res U S. 1947;20:33.
  2. Quick AJ, Hussey CV. Hereditary hypoprothrombinaemias. Lancet. 1962;1:173-7.
  3. Quick AJ, Pisciotta AV, Hussey CV. Congenital hypoprothrombinemic states. AMA Arch Intern Med. 1955;95:2-14.
  4. Shapiro SS, Martinez J, Holburn RR. Congenital dysprothrombinemia: an inherited structural disorder of human prothrombin. J Clin Invest. 1969;48:2251-9.
  5. Lancellotti S, Basso M, De Cristofaro R. Congenital prothrombin deficiency: an update. Semin Thromb Hemost. 2013;39:596-606.
  6. Girolami A, Scarano L, Saggiorato G, Girolami B, Bertomoro A, Marchiori A. Congenital deficiencies and abnormalities of prothrombin. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 1998;9:557-69.
  7. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76:1-16.
  8. Bianchini EP, Orcutt SJ, Panizzi P, Bock PE, Krishnaswamy S. Ratcheting of the substrate from the zymogen to proteinase conformations directs the sequential cleavage of prothrombin by prothrombinase. Proc Natl Acad Sci U S A. 2005;102:10099-104.
  9. Meeks SL, Abshire TC. Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment. Haemophilia. 2008;14:1159-63.
  10. Girolami A, Cosi E, Ferrari S, Lombardi AM, Girolami B. New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice. J Thromb Thrombolysis. 2017;44:71-5.
  11. Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost. 2006;32 Suppl 1:3-15.
  12. Peterson EA, Sutherland MR, Nesheim ME, Pryzdial EL. Thrombin induces endothelial cell-surface exposure of the plasminogen receptor annexin 2. J Cell Sci. 2003;116:2399-408.
  13. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-64.
  14. Peyvandi F, Kunicki T, Lillicrap D. Genetic sequence analysis of inherited bleeding diseases. Blood. 2013;122:3423-31.
  15. Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmback K, et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A. 1998;95:7597-602.
  16. Sun WY, Coleman MJ, Witte DP, Degen SJ. Rescue of prothrombin-deficiency by transgene expression in mice. Thromb Haemost. 2002;88:984-91.
  17. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104:1243-52.
  18. Akhavan S, Mannucci PM, Lak M, Mancuso G, Mazzucconi MG, Rocino A, et al. Identification and three-dimensional structural analysis of nine novel mutations in patients with prothrombin deficiency. Thromb Haemost. 2000;84:989-97.
  19. Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia. 2002;8:308-21.
  20. Miyawaki Y, Suzuki A, Fujita J, Maki A, Okuyama E, Murata M, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med. 2012;366:2390-6.
  21. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-703.
  22. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol. 1997;98:907-9.
  23. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706-8.
  24. Zivelin A, Rosenberg N, Faier S, Kornbrot N, Peretz H, Mannhalter C, et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood. 1998;92:1119-24.
  25. Peyvandi F, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. Semin Thromb Hemost. 2013;39:579-84.
  26. Kattlove HE, Shapiro SS, Spivack M. Hereditary prothrombin deficiency. N Engl J Med. 1970;282:57-61.
  27. Peyvandi F, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A, et al. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost. 2012;10:1938-43.
  28. Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood. 2015;125:2052-61.
  29. Akhavan S, De Cristofaro R, Peyvandi F, Lavoretano S, Landolfi R, Mannucci PM. Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood. 2002;100:1347-53.
  30. Miyata T, Aruga R, Umeyama H, Bezeaud A, Guillin MC, Iwanaga S. Prothrombin Salakta: substitution of glutamic acid-466 by alanine reduces the fibrinogen clotting activity and the esterase activity. Biochemistry. 1992;31:7457-62.
  31. Morishita E, Saito M, Kumabashiri I, Asakura H, Matsuda T, Yamaguchi K. Prothrombin Himi: a compound heterozygote for two dysfunctional prothrombin molecules (Met-337–>Thr and Arg-388–>His). Blood. 1992;80:2275-80.
  32. Brenner B, Kuperman AA, Watzka M, Oldenburg J. Vitamin K-dependent coagulation factors deficiency. Semin Thromb Hemost. 2009;35:439-46.
  33. Castaman G, Linari S. Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders. J Clin Med. 2017;6.
  34. Mulliez SM, De Keyser F, Verbist C, Vantilborgh A, Wijns W, Beukinga I, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Lupus. 2015;24:736-45.
  35. Sarker T, Roy S, Hollon W, Rajpurkar M. Lupus anticoagulant acquired hypoprothrombinemia syndrome in childhood: two distinct patterns and review of the literature. Haemophilia. 2015;21:754-60.
  36. Peyvandi F, Menegatti M. Treatment of rare factor deficiencies in 2016. Hematology Am Soc Hematol Educ Program. 2016;2016:663-9.
  37. Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia. 2001;7 Suppl 1:16-22.
  38. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci. 2006;35:83-90.
  39. Mumford AD, Ackroyd S, Alikhan R, Bowles L, Chowdary P, Grainger J, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2014;167:304-26.
  40. Lobel JS, Majumdar S, Kovats-Bell S. Successful prophylactic treatment for bleeding in a girl with severe hereditary prothrombin deficiency using a prothrombin complex concentrate (Bebulin VH). J Pediatr Hematol Oncol. 2004;26:480-3.
  41. Catanzarite VA, Novotny WF, Cousins LM, Schneider JM. Pregnancies in a patient with congenital absence of prothrombin activity: case report. Am J Perinatol. 1997;14:135-8.
  42. Ruiz-Saez A. Occurrence of thrombosis in rare bleeding disorders. Semin Thromb Hemost. 2013;39:684-92.
  43. Zekavat OR, Haghpanah S, Dehghani J, Afrasiabi A, Peyvandi F, Karimi M. Comparison of thrombin generation assay with conventional coagulation tests in evaluation of bleeding risk in patients with rare bleeding disorders. Clin Appl Thromb Hemost. 2014;20:637-44.
  44. Zia AN, Chitlur M, Rajpurkar M, Ozgonenel B, Lusher J, Callaghan JH, et al. Thromboelastography identifies children with rare bleeding disorders and predicts bleeding phenotype. Haemophilia. 2015;21:124-32.
  45. Peyvandi F, Hayward CP. Genomic approaches to bleeding disorders. Haemophilia. 2016;22 Suppl 5:42-5.

Acknowledgment

Rare Coagulation Disorders Resource Room, an extension of the RBDD Registry (eu.rbdd.org), was developed in collaboration with the Indiana Hemophilia & Thrombosis Center (www.innovativehematology.org).

The Resource Room serves as a platform to promote international collaboration to increase knowledge of these very rare disorders and to improve the care of affected individuals. The international RBDD mission, under the leadership of Dr. Peyvandi, will continue to be expanded over time.

The Resource Room thanks all contributing authors of the website articles that have made this valuable information available to the global community of both individuals affected with rare coagulation disorders and their healthcare providers.

A collaboration of RBDD & IHTC

Quick Links